NZ707389A - Process for preparing bile acid derivatives - Google Patents

Process for preparing bile acid derivatives

Info

Publication number
NZ707389A
NZ707389A NZ707389A NZ70738913A NZ707389A NZ 707389 A NZ707389 A NZ 707389A NZ 707389 A NZ707389 A NZ 707389A NZ 70738913 A NZ70738913 A NZ 70738913A NZ 707389 A NZ707389 A NZ 707389A
Authority
NZ
New Zealand
Prior art keywords
acid derivatives
bile acid
formula
preparing bile
preparing
Prior art date
Application number
NZ707389A
Other languages
English (en)
Inventor
Roberto Pellicciari
Antimo Gioiello
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Priority to NZ745013A priority Critical patent/NZ745013A/en
Publication of NZ707389A publication Critical patent/NZ707389A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ707389A 2012-10-26 2013-10-25 Process for preparing bile acid derivatives NZ707389A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ745013A NZ745013A (en) 2012-10-26 2013-10-25 Process for preparing bile acid derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261718966P 2012-10-26 2012-10-26
PCT/US2013/066917 WO2014066819A1 (en) 2012-10-26 2013-10-25 Process for preparing bile acid derivatives

Publications (1)

Publication Number Publication Date
NZ707389A true NZ707389A (en) 2018-08-31

Family

ID=50545344

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ707389A NZ707389A (en) 2012-10-26 2013-10-25 Process for preparing bile acid derivatives
NZ745013A NZ745013A (en) 2012-10-26 2013-10-25 Process for preparing bile acid derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ745013A NZ745013A (en) 2012-10-26 2013-10-25 Process for preparing bile acid derivatives

Country Status (22)

Country Link
US (2) US9777038B2 (enExample)
EP (1) EP2912013B1 (enExample)
JP (1) JP6272888B2 (enExample)
KR (1) KR102068381B1 (enExample)
CN (2) CN105102425B (enExample)
AU (1) AU2013334122B2 (enExample)
BR (1) BR112015009395A2 (enExample)
CA (1) CA2889592A1 (enExample)
CY (1) CY1119731T1 (enExample)
DK (1) DK2912013T3 (enExample)
ES (1) ES2655034T3 (enExample)
HK (1) HK1253301A1 (enExample)
HU (1) HUE036887T2 (enExample)
IL (1) IL238454B (enExample)
MX (1) MX361653B (enExample)
NO (1) NO2968302T3 (enExample)
NZ (2) NZ707389A (enExample)
PL (1) PL2912013T3 (enExample)
PT (1) PT2912013T (enExample)
SG (1) SG11201503247UA (enExample)
SM (1) SMT201700602T1 (enExample)
WO (1) WO2014066819A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE036887T2 (hu) 2012-10-26 2018-08-28 Intercept Pharmaceuticals Inc Eljárás epesav-származékok elõállítására
EP3626725B1 (en) * 2014-05-29 2022-11-30 Bar Pharmaceuticals S.r.l. Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases
EA033445B1 (ru) 2014-11-19 2019-10-31 Nzp Uk Ltd 5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
EP3221333B1 (en) 2014-11-19 2019-07-24 NZP UK Limited 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators
EP3221331B1 (en) 2014-11-19 2019-09-18 Nzp Uk Limited 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators
JP6698085B2 (ja) 2014-11-19 2020-05-27 エヌゼットピー ユーケー リミテッド ステロイドFXRモジュレーター製造のための中間体としての6α−アルキル−6,7−ジオン−ステロイド
CN104672290B (zh) * 2015-01-05 2017-06-06 北京普禄德医药科技有限公司 一种用于预防或治疗fxr‑介导的疾病的药物及其制备方法和用途
TN2017000344A1 (en) 2015-02-06 2019-01-16 Intercept Pharmaceuticals Inc Pharmaceutical compositions for combination therapy
CN108350020A (zh) * 2015-09-24 2018-07-31 英特塞普特医药品公司 用于制备胆汁酸衍生物的方法和中间体
KR20180067699A (ko) 2015-11-06 2018-06-20 인터셉트 파마슈티컬즈, 인크. 오베티콜산 및 이의 유도체의 제조 방법
WO2017142895A1 (en) * 2016-02-15 2017-08-24 Regents Of The University Of Minnesota Compositions and methods for treating clostridium associated diseases
WO2017180577A1 (en) 2016-04-13 2017-10-19 Intercept Pharmaceuticals, Inc. Methods of treating cancer
TW201738254A (zh) * 2016-04-19 2017-11-01 英特賽普醫藥品公司 奧貝膽酸及其衍生物之製備方法
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
CA3038534A1 (en) * 2016-09-30 2018-04-05 Intercept Pharmaceuticals, Inc. Crystalline forms of a bile acid derivative
MX2020000873A (es) * 2017-07-24 2020-07-22 Intercept Pharmaceuticals Inc Derivados de ácidos biliares marcados isotópicamente.
WO2019020067A1 (zh) * 2017-07-26 2019-01-31 正大天晴药业集团股份有限公司 甾体类衍生物fxr激动剂的制备方法
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
EA202193334A1 (ru) 2019-05-30 2022-03-14 Интерсепт Фармасьютикалз, Инк. Фармацевтические композиции, содержащие агонист fxr и фибрат, для применения при лечении холестатического заболевания печени
BR112022006546A2 (pt) 2019-10-07 2022-08-30 Kallyope Inc Agonistas de gpr119
CA3173731A1 (en) 2020-02-28 2021-09-02 Kallyope, Inc. Gpr40 agonists
CN116323608A (zh) 2020-05-19 2023-06-23 卡尔优普公司 Ampk活化剂
EP4172162A4 (en) 2020-06-26 2024-08-07 Kallyope, Inc. AMPK ACTIVATORS
WO2022059948A1 (ko) 2020-09-18 2022-03-24 서울대학교 산학협력단 소디움 타우로디옥시콜레이트의 대량 생산 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216015A (en) * 1991-02-05 1993-06-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having hypocholesterolemic properties
ATE303399T1 (de) * 2001-03-12 2005-09-15 Intercept Pharmaceuticals Inc Steroide als agonisten für fxr
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
CN101522703B (zh) * 2006-06-27 2013-04-17 英特塞普特医药品公司 胆酸派生物及其在制备预防或治疗fxr介导的疾病或状况的药物中的应用
US9943614B2 (en) * 2008-06-17 2018-04-17 Brigham Young University Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods
EA020310B1 (ru) * 2008-07-30 2014-10-30 Интерсепт Фармасьютикалз, Инк. Модуляторы рецептора tgr5 и их применение
CA2744135C (en) * 2008-11-19 2017-07-04 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
HUE036887T2 (hu) 2012-10-26 2018-08-28 Intercept Pharmaceuticals Inc Eljárás epesav-származékok elõállítására

Also Published As

Publication number Publication date
JP2015533852A (ja) 2015-11-26
ES2655034T3 (es) 2018-02-16
KR20150074062A (ko) 2015-07-01
SMT201700602T1 (it) 2018-03-08
CA2889592A1 (en) 2014-05-01
NO2968302T3 (enExample) 2018-02-03
KR102068381B1 (ko) 2020-01-20
EP2912013A1 (en) 2015-09-02
HK1253301A1 (zh) 2019-06-14
HK1214239A1 (zh) 2016-07-22
HUE036887T2 (hu) 2018-08-28
JP6272888B2 (ja) 2018-01-31
CY1119731T1 (el) 2018-06-27
AU2013334122B2 (en) 2017-11-02
US9777038B2 (en) 2017-10-03
AU2013334122A1 (en) 2015-05-14
US20180079776A1 (en) 2018-03-22
SG11201503247UA (en) 2015-06-29
CN105102425A (zh) 2015-11-25
MX2015005286A (es) 2015-10-29
BR112015009395A2 (pt) 2017-07-04
EP2912013A4 (en) 2016-06-01
US10202414B2 (en) 2019-02-12
NZ745013A (en) 2019-08-30
CN108250264A (zh) 2018-07-06
MX361653B (es) 2018-12-13
DK2912013T3 (en) 2018-01-15
WO2014066819A1 (en) 2014-05-01
CN105102425B (zh) 2018-04-10
PT2912013T (pt) 2018-01-03
US20150291653A1 (en) 2015-10-15
IL238454B (en) 2018-11-29
PL2912013T3 (pl) 2018-05-30
IL238454A0 (en) 2015-06-30
EP2912013B1 (en) 2017-10-11

Similar Documents

Publication Publication Date Title
MX361653B (es) Procedimiento para la preparación de derivados del ácido biliar.
IN2012DN02751A (enExample)
EA033513B1 (ru) Способы получения хинолиновых соединений и фармацевтических композиций, содержащих такие соединения
IN2015DN00598A (enExample)
MD20180040A2 (ro) Inhibitori ai virusului hepatic C
PH12015501226A1 (en) Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing the same
PH12015500334A1 (en) Azaindole carboxylic acid amides and azaindole thiocarboxylic acid amides for use as insecticides and acaricides
IN2014CN04449A (enExample)
JO3318B1 (ar) مثبطات bace
PH12014502492A1 (en) Pyrazole compounds as sglt1 inhibitors
MX2012001411A (es) Proceso para la preparacion de derivados de acido 1-(2-halobifenil-4-il)-ciclopropanocarboxilico.
PH12015501146A1 (en) Hydantoin derivative
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
WO2012140490A3 (en) Processes for preparing pitavastatin calcium
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
MX2013000294A (es) Intermedios y procedimiento de preparación de un inhibidor específico de la trombina.
MX350430B (es) Proceso para preparar compuestos acido 4-amino-5-bifenil-4-il-2-hi droximetil-2-metil-pentanoico.
MX2014009084A (es) Derivados de pirimidooxazocina como inhibidores de mtor.
MX364529B (es) Nuevos ligandos del receptor de estrógeno.
SG10201901578UA (en) Processes for the preparation of pyrimidinylcyclopentane compounds
MX361998B (es) Procedimiento de preparacion de derivados de acido 4-haloalquil-3-mercapto-2 sustituido-hidroxibenzoico.
IN2012DN02000A (enExample)
WO2012150183A8 (en) Crystalline sodium salt of an hiv integrase inhibitor
WO2014024203A8 (en) An improved process for - the preparation of dexmethylphenidate hydrochloride.
IN2014DN07498A (enExample)

Legal Events

Date Code Title Description
PSEA Patent sealed
S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 OCT 2020 BY COMPUTER PACKAGES INC

Effective date: 20191001

S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 OCT 2021 BY COMPUTER PACKAGES INC

Effective date: 20201001

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 OCT 2022 BY COMPUTER PACKAGES INC

Effective date: 20210930

LAPS Patent lapsed